KSPM
Search
- Page Path
- HOME > Search
Original Article
- Association Between Angiotensin II Receptor Blockers and the Risk of Lung Cancer Among Patients With Hypertension From the Korean National Health Insurance Service-National Health Screening Cohort
- Sungji Moon, Hae-Young Lee, Jieun Jang, Sue K. Park
- J Prev Med Public Health. 2020;53(6):476-486. Published online November 3, 2020
- DOI: https://doi.org/10.3961/jpmph.20.405
- 5,899 View
- 161 Download
- 6 Crossref
-
Abstract
PDF
Supplementary Material - Objectives
The objective of this study was to estimate the risk of lung cancer in relation to angiotensin II receptor blocker (ARB) use among patients with hypertension from the Korean National Health Insurance Service-National Health Screening Cohort. Methods: We conducted a retrospective cohort study of patients with hypertension who started to take antihypertensive medications and had a treatment period of at least 6 months. We calculated the weighted hazard ratios (HRs) and their 95% confidence intervals (CIs) of lung cancer associated with ARB use compared with calcium channel blocker (CCB) use using inverse probability treatment weighting. Results: Among a total of 60 469 subjects with a median follow-up time of 7.8 years, 476 cases of lung cancer were identified. ARB use had a protective effect on lung cancer compared with CCB use (HR, 0.75; 95% CI, 0.59 to 0.96). Consistent findings were found in analyses considering patients who changed or discontinued their medication (HR, 0.50; 95% CI, 0.32 to 0.77), as well as for women (HR, 0.56; 95% CI, 0.34 to 0.93), patients without chronic obstructive pulmonary disease (HR, 0.75; 95% CI, 0.56 to 1.00), never-smokers (HR, 0.64; 95% CI, 0.42 to 0.99), and non-drinkers (HR, 0.69; 95% CI, 0.49 to 0.97). In analyses with different comparison antihypertensive medications, the overall protective effects of ARBs on lung cancer risk remained consistent. Conclusions: The results of the present study suggest that ARBs could decrease the risk of lung cancer. More evidence is needed to establish the causal effect of ARBs on the incidence of lung cancer. -
Summary
Citations
Citations to this article as recorded by
- Effects of ACE inhibitors/ARBs on lung cancer; an updated mini-review on recent data
Zahra Golestani Hotkani, Tella Sadighpour, Ali Shirbacheh, Kamran Shirbache
Journal of Renal Endocrinology.2024; 10: e25175. CrossRef - Association between Statins and Incidence of Cancer in Patients with Dyslipidemia Using Large-Scale Health Insurance Claims Data
Ayako Maeda-Minami, Masayuki Takagi, Yasunari Mano, Hideki Ishikawa, Yutaka Matsuyama, Michihiro Mutoh
Cancer Prevention Research.2023; 16(1): 37. CrossRef - Angiotensin Receptor Blocker Associated with a Decreased Risk of Lung Cancer: An Updated Meta-Analysis
Zexu Wang, Lingyun Wei, Cheng Yin, Wang Li, Bing Wan
Journal of Personalized Medicine.2023; 13(2): 243. CrossRef - The association between angiotensin receptor blockers and lung, bladder, and colon cancer development: A 10-year multicentric retrospective Lebanese study
Yara G. Dagher, Sandra El Helou, Karen G. Haifa, Issam G. Chalhoub, Rita T. Boulos, Bachir Atallah, Fadi Nasr, Issam Kassab, Mirna N. Chahine
Medicine.2023; 102(36): e34901. CrossRef - Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers and Cancer Risk: An Updated Meta-Analysis of Observational Studies
Kayeong Shin, Jiwoo Yang, Yeuni Yu, Eunjeong Son, Kihun Kim, Yun Hak Kim
SSRN Electronic Journal .2022;[Epub] CrossRef - The Effect of Local Renin Angiotensin System in the Common Types of Cancer
Moudhi Almutlaq, Abir Abdullah Alamro, Hassan S. Alamri, Amani Ahmed Alghamdi, Tlili Barhoumi
Frontiers in Endocrinology.2021;[Epub] CrossRef
First
Prev
